[go: up one dir, main page]

WO2008131859A3 - Use of cyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia - Google Patents

Use of cyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia Download PDF

Info

Publication number
WO2008131859A3
WO2008131859A3 PCT/EP2008/003008 EP2008003008W WO2008131859A3 WO 2008131859 A3 WO2008131859 A3 WO 2008131859A3 EP 2008003008 W EP2008003008 W EP 2008003008W WO 2008131859 A3 WO2008131859 A3 WO 2008131859A3
Authority
WO
WIPO (PCT)
Prior art keywords
pulmonary arterial
hypertonia
treating pulmonary
cyclically substituted
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/003008
Other languages
German (de)
French (fr)
Other versions
WO2008131859A2 (en
Inventor
Thomas Lampe
Eva-Maria Becker
Raimund Kast
Hartmut Beck
Mario Jeske
Joachim Schuhmacher
Friederike Stoll
Martina Klein
Metin Akbaba
Andreas Knorr
Johannes-Peter Stasch
Lars Baerfacker
Alexander Hillisch
Gunter Karig
Mark Meininghaus
Karl-Heinz Schlemmer
Rudolf Schohe-Loop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to CA002685134A priority Critical patent/CA2685134A1/en
Publication of WO2008131859A2 publication Critical patent/WO2008131859A2/en
Publication of WO2008131859A3 publication Critical patent/WO2008131859A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of cyclically substituted furopyrimidine derivatives of formula (I) for the treatment and/or prophylaxis of pulmonary arterial hypertonia and other forms of pulmonary hypertonia and to the use of said derivatives for producing medicaments for the treatment and/or prophylaxis of pulmonary arterial hypertonia and other forms of pulmonary hypertonia.
PCT/EP2008/003008 2007-04-26 2008-04-16 Use of cyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia Ceased WO2008131859A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002685134A CA2685134A1 (en) 2007-04-26 2008-04-16 Use of cyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007019690.5 2007-04-26
DE102007019690A DE102007019690A1 (en) 2007-04-26 2007-04-26 Use of cyclic substituted furopyrimidine derivatives for the treatment of pulmonary arterial hypertension

Publications (2)

Publication Number Publication Date
WO2008131859A2 WO2008131859A2 (en) 2008-11-06
WO2008131859A3 true WO2008131859A3 (en) 2009-07-16

Family

ID=39777458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/003008 Ceased WO2008131859A2 (en) 2007-04-26 2008-04-16 Use of cyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia

Country Status (3)

Country Link
CA (1) CA2685134A1 (en)
DE (1) DE102007019690A1 (en)
WO (1) WO2008131859A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211655A1 (en) 2018-10-31 2021-08-24 Gilead Sciences Inc 6-AZABENZIMIDAZOLE COMPOUNDS SUBSTITUTED AS HPK1 INHIBITORS
TWI721624B (en) 2018-10-31 2021-03-11 美商基利科學股份有限公司 Substituted 6-azabenzimidazole compounds
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2022119823A1 (en) * 2020-12-04 2022-06-09 The Johns Hopkins University Compounds and their use for treating neuropathic pain

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1817146A1 (en) * 1968-01-05 1969-11-27 Pfizer & Co C 4-aminofuro [2,3-d] pyrimidines and their use as relaxants for smooth muscles
EP1018514A1 (en) * 1998-07-22 2000-07-12 Suntory Limited NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT
WO2000075145A1 (en) * 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1132093A1 (en) * 1999-09-17 2001-09-12 Suntory Limited Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing nf-kappa b inhibitors as the active ingredient
WO2002092603A1 (en) * 2001-05-14 2002-11-21 Novartis Ag Oxazolo-and furopyrimidines and their use in medicaments against tumors
WO2003022852A2 (en) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
WO2005092896A1 (en) * 2004-03-12 2005-10-06 Korea Institute Of Science And Technology Compound for inhibiting tyrosine kinase activity of ddr2 protein
WO2005121149A1 (en) * 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
WO2006004658A2 (en) * 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
WO2007079861A1 (en) * 2005-12-21 2007-07-19 Bayer Healthcare Ag Novel, cyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19834044A1 (en) 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
DE19943635A1 (en) 1999-09-13 2001-03-15 Bayer Ag Novel aminodicarboxylic acid derivatives with pharmaceutical properties
DE19943636A1 (en) 1999-09-13 2001-03-15 Bayer Ag Novel dicarboxylic acid derivatives with pharmaceutical properties
DE19943639A1 (en) 1999-09-13 2001-03-15 Bayer Ag Dicarboxylic acid derivatives with novel pharmaceutical properties
DE19943634A1 (en) 1999-09-13 2001-04-12 Bayer Ag Novel dicarboxylic acid derivatives with pharmaceutical properties
AR031176A1 (en) 2000-11-22 2003-09-10 Bayer Ag NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE
DE10110749A1 (en) 2001-03-07 2002-09-12 Bayer Ag Substituted aminodicarboxylic acid derivatives
DE10110750A1 (en) 2001-03-07 2002-09-12 Bayer Ag Novel aminodicarboxylic acid derivatives with pharmaceutical properties
DE10141212A1 (en) 2001-08-22 2003-03-06 Bayer Ag New 4-aminofuropyrimidines and their use
AU2002361992A1 (en) 2001-12-20 2003-07-09 Bayer Aktiengesellschaft 1,4-dihydro-1,4-diphenylpyridine derivatives
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
ES2293077T3 (en) 2002-08-27 2008-03-16 Bayer Healthcare Ag DERIVATIVES OF DIHYDROPIRIDINONE AS HNE INHABITORS.
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
EP1539710B1 (en) 2002-09-10 2010-10-27 Bayer Schering Pharma Aktiengesellschaft Heterocyclic derivatives
KR20050042190A (en) 2002-09-10 2005-05-04 바이엘 헬스케어 아게 Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
WO2005080372A1 (en) 2004-02-19 2005-09-01 Bayer Healthcare Ag Dihydropyridinone derivatives
CA2557272C (en) 2004-02-26 2012-09-11 Bayer Healthcare Ag Heterocyclic derivatives
US8101615B2 (en) 2004-02-26 2012-01-24 Bayer Pharma Aktiengesellschaft 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1817146A1 (en) * 1968-01-05 1969-11-27 Pfizer & Co C 4-aminofuro [2,3-d] pyrimidines and their use as relaxants for smooth muscles
EP1018514A1 (en) * 1998-07-22 2000-07-12 Suntory Limited NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT
WO2000075145A1 (en) * 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1132093A1 (en) * 1999-09-17 2001-09-12 Suntory Limited Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing nf-kappa b inhibitors as the active ingredient
WO2002092603A1 (en) * 2001-05-14 2002-11-21 Novartis Ag Oxazolo-and furopyrimidines and their use in medicaments against tumors
WO2003022852A2 (en) * 2001-09-11 2003-03-20 Smithkline Beecham Corporation Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
WO2005092896A1 (en) * 2004-03-12 2005-10-06 Korea Institute Of Science And Technology Compound for inhibiting tyrosine kinase activity of ddr2 protein
WO2005121149A1 (en) * 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
WO2006004658A2 (en) * 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
WO2007079861A1 (en) * 2005-12-21 2007-07-19 Bayer Healthcare Ag Novel, cyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 2002 (2002-11-01), GALIÈ NAZZARENO ET AL: "Emerging medical therapies for pulmonary arterial hypertension.", XP002528176, Database accession no. NLM12525997 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 2006 (2006-09-01), BRESSER PAUL ET AL: "Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.", XP002528177, Database accession no. NLM16963540 *
PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY SEP 2006, vol. 3, no. 7, September 2006 (2006-09-01), pages 594 - 600, ISSN: 1546-3222 *
PROGRESS IN CARDIOVASCULAR DISEASES 2002 NOV-DEC, vol. 45, no. 3, November 2002 (2002-11-01), pages 213 - 224, ISSN: 0033-0620 *

Also Published As

Publication number Publication date
CA2685134A1 (en) 2008-11-06
DE102007019690A1 (en) 2008-10-30
WO2008131859A2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
MX2010006033A (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof.
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
WO2010057101A3 (en) Compounds useful as hiv blockers
WO2009026179A3 (en) Antiinfective proanthocyanidin compounds and methods of use thereof
WO2007125105A3 (en) Benzamide glucokinase activators
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
UA95103C2 (en) Substituted arylsulfonamides as antiviral agents
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
MY150702A (en) Substituted 4-phenyltetrahydroisoquinonelines, method of producing them, their use as medicament, and also medicament containing them
WO2009074247A8 (en) Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
TW200621765A (en) Substituted phenylaminothiazoles and their use
MY150931A (en) Substituted oxazolidinones and their use
WO2006072458A3 (en) Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
MX2007000224A (en) Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting.
MX2007012538A (en) Use of lgg in the manufacture of a medicament for the prevention or treatment of respiratory allergies.
NO20083901L (en) Fixed-dose association of phytate and zinc
MX2010002007A (en) Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors.
WO2008046407A3 (en) Use of deuterium dioxide for treating hyperproliferative skin diseases
DOP2006000062A (en) PYRIMIDINCARBOXILIC ACID DERIVATIVES AND ITS USE
WO2008131859A3 (en) Use of cyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia
ATE380188T1 (en) SUBSTITUTED QUINOLONES
UA94080C2 (en) Acyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases
WO2006023843A3 (en) Novel heterocycles
WO2006089664A3 (en) Heterocyclylamide-substituted imidazoles
WO2010107791A3 (en) Pyrazinoisoquinoline compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08735263

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008735263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2685134

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010504502

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP